KWKevin D. Wells

Kevin D. Wells

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kevin D. Wells has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Expression of Human Thrombomodulin by Porcine Endothelium Attenuates Thrombus Formation and Platelet Activation in a Dynamic Shear Flow Model

    by Megan Dufault, Sayed‐Amir Sanatkar, Zahra Habibabady, Victoria Diaz, Jonathan Schulz, Caroline Gomes Lucas, Kevin D. Wells, Kristin M. Whitworth, David Ayares, Richard N. Pierson

    Long term xenografts often fail in association with evidence of coagulation pathway dysregulation, which may be caused in part by the inefficient binding of inactivated protein C (PC) to porcine thrombomodulin (TBM). This study evaluates the effect of human TBM (hTBM) expression by genetically modified pig endothelium on human platelet activation, adhesion, and aggregation within a dynamic in vitro xenoperfusion model. Porcine aortic endothelial cells (PAECs) with a variety of genetic modifications and immortalized human coronary endothelial cells (HCECs) ( n = 9) were cultured to confluence in microfluidic channels and perfused for one hour with human whole blood stained with 0.5 mM Calcein to visualize thrombosis formation. After one hour of perfusion, platelet adhesion (as percent surface area coverage) and aggregation (fluorescence intensity) were significantly reduced in association with human APC (hAPC) pretreatment of GTKO, and with DKO.hCD55.hTBM or 10‐GE ECs relative to GT/DKO ± hCD55 ECs. Fold change in frequency of activated (CD62P+) platelets in channel effluent was significantly decreased in association with GTKO+hAPC (1.5 ± 0.03 p = 0.01, n = 6), and DKO.hCD55.hTBM (1.6 ± 0.03 p = 0.02, n = 12) or 10‐GE ECs (1.3 ± 0.04 p < 0.0001, n = 9) relative to GT/DKO ± hCD55 ECs (1.8 ± 0.07, n = 8). No significant difference was observed between DKO.hCD55.hTBM and GTKO+hAPC. We conclude that, under conditions mimicking microcirculatory flow, hTBM expression confers anti‐thrombotic effects comparable to those with hAPC pretreatment of GTKO ECs. Consequently, hTBM expression is a promising method to inhibit platelet dysregulation in xenotransplant models.

  • Chloride channel accessory 1 gene deficiency causes selective loss of mucus production in a new pig model

    by Shamus P. Keeler, Jennifer Yantis, Benjamin J. Gerovac, Samuel L. Youkilis, Stephanie Podgorny, Dailing Mao, Yong Zhang, Kristin M. Whitworth, Bethany Redel, Melissa S. Samuel, et al.

    Morbidity and mortality of respiratory diseases are linked to airway obstruction by mucus but there are still no specific, safe, and effective drugs to correct this phenotype. The need for better treatment requires a new understanding of the basis for mucus production. In that regard, studies of human airway epithelial cells in primary culture show that a mucin granule constituent known as chloride channel accessory 1 (CLCA1) is required for inducible expression of the inflammatory mucin MUC5AC in response to potent type 2 cytokines. However, it remained uncertain whether CLCLA1 is necessary for mucus production in vivo. Conventional approaches to functional biology using targeted gene knockout were difficult due to the functional redundancy of additional Clca genes in mice not found in humans. We reasoned that CLCA1 function might be better addressed in pigs that maintain the same four-member CLCA gene locus and the corresponding mucosal and submucosal populations of mucous cells found in humans. Here we develop to our knowledge the first CLCA1-gene-deficient ( CLCA1–/–) pig and show that these animals exhibit loss of MUC5AC+ mucous cells throughout the airway mucosa of the lung without affecting comparable cells in the tracheal mucosa or MUC5B+ mucous cells in submucosal glands. Similarly, CLCA1–/– pigs exhibit loss of MUC5AC+ mucous cells in the intestinal mucosa without affecting MUC2+ mucous cells. These data establish CLCA1 function for controlling MUC5AC expression as a marker of mucus production and provide a new animal model to study mucus production at respiratory and intestinal sites.


  • Open Access

    Serologic titers to Leptospira in vaccinated pigs and interpretation for surveillance

    by Susan K. Schommer, Nicholas Harrison, Michael Linville, Melissa S. Samuel, Sabrina L. Hammond, Kevin D. Wells, Randall S. Prather

    Diagnosis and surveillance of pathogenic Leptospira is difficult as organisms may be intermittently shed and in small numbers. Therefore, serologic testing by the microscopic agglutination test (MAT) is the primary screening method for leptospirosis. While a MAT titer ≥1:100 is considered to be a positive result, interpretation is complicated by the use of commercial vaccines in pigs. Most guidelines for interpretation of MAT titers in pigs were published in the 1970’s and 1980’s, prior to the development of the current multivalent vaccines. We evaluated MAT titers in routinely vaccinated healthy research pigs compared to their unvaccinated cohorts. Our study confirmed previous reports that the Pomona serovar elicits minimal antibody response even after a second booster 6 months after initial vaccination. However, MAT titers of ≥1:3,200 were detected as early as 4 weeks post initial vaccination for serovars Bratislava and Icterohaemorrhagiae and remained as high as ≥1:1,600 prior to booster at 24 weeks post vaccination. Our study determined that high levels of MAT titers can occur from vaccination alone and high titers are not necessarily indicative of infection. Therefore, the interpretation of MAT titers as indicators of Leptospira infection should be readdressed.


  • Effects of RAD51-stimulatory compound 1 (RS-1) and its vehicle, DMSO, on pig embryo culture

    by C.G. Lucas, B.K. Redel, P.R. Chen, L.D. Spate, R.S. Prather, K.D. Wells


  • Open Access

    Cardiovascular Development and Congenital Heart Disease Modeling in the Pig

    by George C. Gabriel, William Devine, Bethany K. Redel, Kristin M. Whitworth, Melissa Samuel, Lee D. Spate, Raissa F. Cecil, Randall S. Prather, Yijen Wu, Kevin D. Wells, et al.

    Background: Modeling cardiovascular diseases in mice has provided invaluable insights into the cause of congenital heart disease. However, the small size of the mouse heart has precluded translational studies. Given current high‐efficiency gene editing, congenital heart disease modeling in other species is possible. The pig is advantageous given its cardiac anatomy, physiology, and size are similar to human infants. We profiled pig cardiovascular development and generated genetically edited pigs with congenital heart defects. Methods and Results: Pig conceptuses and fetuses were collected spanning 7 stages (day 20 to birth at day 115), with at least 3 embryos analyzed per stage. A combination of magnetic resonance imaging and 3‐dimensional histological reconstructions with episcopic confocal microscopy were conducted. Gross dissections were performed in late‐stage or term fetuses by using sequential segmental analysis of the atrial, ventricular, and arterial segments. At day 20, the heart has looped, forming a common atria and ventricle and an undivided outflow tract. Cardiac morphogenesis progressed rapidly, with atrial and outflow septation evident by day 26 and ventricular septation completed by day 30. The outflow and atrioventricular cushions seen at day 20 undergo remodeling to form mature valves, a process continuing beyond day 42. Genetically edited pigs generated with mutation in chromatin modifier SAP130 exhibited tricuspid dysplasia, with tricuspid atresia associated with early embryonic lethality. Conclusions: The major events in pig cardiac morphogenesis are largely complete by day 30. The developmental profile is similar to human and mouse, indicating gene edited pigs may provide new opportunities for preclinical studies focused on outcome improvements for congenital heart disease.


  • Open Access

    A porcine model of phenylketonuria generated by CRISPR/Cas9 genome editing

    by Erik A. Koppes, Bethany K. Redel, Marie A. Johnson, Kristen J. Skvorak, Lina Ghaloul-Gonzalez, Megan E. Yates, Dale W. Lewis, Susanne M. Gollin, Yijen L. Wu, Shawn E. Christ, et al.

    Phenylalanine hydroxylase–deficient (PAH-deficient) phenylketonuria (PKU) results in systemic hyperphenylalaninemia, leading to neurotoxicity with severe developmental disabilities. Dietary phenylalanine (Phe) restriction prevents the most deleterious effects of hyperphenylalaninemia, but adherence to diet is poor in adult and adolescent patients, resulting in characteristic neurobehavioral phenotypes. Thus, an urgent need exists for new treatments. Additionally, rodent models of PKU do not adequately reflect neurocognitive phenotypes, and thus there is a need for improved animal models. To this end, we have developed PAH -null pigs. After selection of optimal CRISPR/Cas9 genome-editing reagents by using an in vitro cell model, zygote injection of 2 sgRNAs and Cas9 mRNA demonstrated deletions in preimplantation embryos, with embryo transfer to a surrogate leading to 2 founder animals. One pig was heterozygous for a PAH exon 6 deletion allele, while the other was compound heterozygous for deletions of exon 6 and of exons 6–7. The affected pig exhibited hyperphenylalaninemia (2000–5000 μM) that was treatable by dietary Phe restriction, consistent with classical PKU, along with juvenile growth retardation, hypopigmentation, ventriculomegaly, and decreased brain gray matter volume. In conclusion, we have established a large-animal preclinical model of PKU to investigate pathophysiology and to assess new therapeutic interventions.


  • A novel swine sex-linked marker and its application across different mammalian species

    by C. G. Lucas, A. M. Spate, M. S. Samuel, L. D. Spate, W. C. Warren, R. S. Prather, K. D. Wells

    Advances in genome editing tools have reduced barriers to the creation of animal models. Due to their anatomical and physiological similarities to humans, there has been a growing need for pig models to study human diseases, for xenotransplantation and translational research. The ability to determine the sex of genetically modified embryos, cells or fetuses is beneficial for every project involving the production of transgenic animals. This strategy can improve the time-efficiency and lower the production costs. Additionally, sex assessment is very useful for wildlife studies to understand population behavior and structure. Thus, we developed a simple and fast PCR-based protocol for sex determination in pigs by using a unique primer set to amplify either the DDX3X or DDX3Y gene. The sex was 100% correctly assigned when tail genomic DNA, Day-35 fetus and hair samples from pigs were used. For both blastocysts and oocytes (84.6% and 96.5% of efficacy, respectively) the unidentified samples were potentially due to a limitation in sample size. Our assay also worked for domestic sheep (Ovis aries), American bison (Bison bison) and European cattle (Bos taurus) samples and by in silico analysis we confirmed X–Y amplicon length polymorphisms for the DDX3 gene in 12 other mammalian species. This PCR protocol for determining sex in pig tissues and cells showed to be simple, specific, highly reproducible and less time consuming as well as an important tool for other livestock species and wildlife studies.


  • Open Access

    New perspective on conceptus estrogens in maternal recognition and pregnancy establishment in the pig†

    by Ashley E Meyer, Caroline A Pfeiffer, Kelsey E Brooks, Lee D Spate, Joshua A Benne, Raissa Cecil, Melissa S Samuel, Clifton N Murphy, Susanta Behura, Megan K McLean, et al.

    The proposed signal for maternal recognition of pregnancy in pigs is estrogen (E2), produced by the elongating conceptuses between days 11 to 12 of pregnancy with a more sustained increase during conceptus attachment and placental development on days 15 to 30. To understand the role of E2 in porcine conceptus elongation and pregnancy establishment, a loss-of-function study was conducted by editing aromatase (CYP19A1) using CRISPR/Cas9 technology. Wild-type (CYP19A1+/+) and (CYP19A1−/−) fibroblast cells were used to create embryos through somatic cell nuclear transfer, which were transferred into recipient gilts. Elongated and attaching conceptuses were recovered from gilts containing CYP19A1+/+ or CYP19A1−/− embryos on day 14 and 17 of pregnancy. Total E2 in the uterine flushings of gilts with CYP19A1−/− embryos was lower than recipients containing CYP19A1+/+ embryos with no difference in testosterone, PGF2α, or PGE2 on either day 14 or 17. Despite the loss of conceptus E2 production, CYP19A1−/− conceptuses were capable of maintaining the corpora lutea. However, gilts gestating CYP19A1−/− embryos aborted between days 27 and 31 of gestation. Attempts to rescue the pregnancy of CYP19A1−/− gestating gilts with exogenous E2 failed to maintain pregnancy. However, CYP19A1−/− embryos could be rescued when co-transferred with embryos derived by in vitro fertilization. Endometrial transcriptome analysis revealed that ablation of conceptus E2 resulted in disruption of a number biological pathways. Results demonstrate that intrinsic E2 conceptus production is not essential for pre-implantation development, conceptus elongation, and early CL maintenance, but is essential for maintenance of pregnancy beyond 30 days .


  • Zygote injection of RNA encoding Cre recombinase results in efficient removal of LoxP flanked neomycin cassettes in pigs

    by Kristin M. Whitworth, Raissa Cecil, Joshua A. Benne, Bethany K. Redel, Lee D. Spate, Melissa S. Samuel, Randall S. Prather, Kevin D. Wells

    Genetically engineered pigs are often created with a targeting vector that contains a loxP flanked selectable marker like neomycin. The Cre–loxP recombinase system can be used to remove the selectable marker gene from the resulting offspring or cell line. Here is described a new method to remove a loxP flanked neomycin cassette by direct zygote injection of an mRNA encoding Cre recombinase. The optimal concentration of mRNA was determined to be 10 ng/μL when compared to 2 and 100 ng/μL (P < 0.0001). Development to the blastocyst stage was 14.1% after zygote injection with 10 ng/μL. This method successfully removed the neomycin cassette in 81.9% of injected in vitro derived embryos; which was significantly higher than the control (P < 0.0001). Embryo transfer resulted in the birth of one live piglet with a Cre deleted neomycin cassette. The new method described can be used to efficiently remove selectable markers in genetically engineered animals without the need for long term cell culture and subsequent somatic cell nuclear transfer.


  • Open Access

    Single step production of Cas9 mRNA for zygote injection

    by Bethany K Redel, Benjamin P Beaton, Lee D Spate, Joshua A Benne, Stephanie L Murphy, Chad W O’gorman, Anna M Spate, Randall S Prather, Kevin D Wells

    Production of Cas9 mRNA in vitro typically requires the addition of a 5' cap and 3' polyadenylation. A plasmid was constructed that harbored the T7 promoter followed by the EMCV IRES and a Cas9 coding region. We hypothesized that the use of the metastasis associated lung adenocarcinoma transcript 1 (Malat1) triplex structure downstream of an IRES/Cas9 expression cassette would make polyadenylation of in vitro produced mRNA unnecessary. A sequence from the mMalat1 gene was cloned downstream of the IRES/Cas9 cassette described above. An mRNA concentration curve was constructed with either commercially available Cas9 mRNA or the IRES/Cas9/triplex, by injection into porcine zygotes. Blastocysts were genotyped to determine if differences existed in the percent of embryos modified. The concentration curve identified differences due to concentration and RNA type injected. Single step production of Cas9 mRNA provides an alternative source of Cas9 for use in zygote injections.